دورية أكاديمية
أعرض في EDS

Cyclooxygenase-2 (COX-2) Expression in Oral Submucous Fibrosis and Oral Squamous Cell Carcinoma: An Immunohistochemical Study.

التفاصيل البيبلوغرافية
العنوان: Cyclooxygenase-2 (COX-2) Expression in Oral Submucous Fibrosis and Oral Squamous Cell Carcinoma: An Immunohistochemical Study.
المؤلفون: Aparnadevi P; Departments of Oral Pathology and Microbiology and, Dental College, Regional Institute of Medical Sciences, Imphal, Manipur, India., Nirmal RM; Department of Oral and Maxillofacial Pathology, Rajah Muthiah Dental College and Hospital, Annamalai University, Chidambaram, Tamil Nadu, India., Veeravarmal V; Department of Oral and Maxillofacial Pathology, Rajah Muthiah Dental College and Hospital, Annamalai University, Chidambaram, Tamil Nadu, India., Nandini DB; Department of Oral Pathology and Microbiology, Dental College, Regional Institute of Medical Sciences, Imphal, Manipur, India., Kalyani C; Independent Researcher, Consultant Oral Pathologist, Tamil Nadu, India., Singh DN; Oral Medicine and Radiology, Dental College, Regional Institute of Medical Sciences, Imphal, Manipur, India., Yoithapprabhunath TR; Department of Oral and Maxillofacial Pathology, Vivekanandha Dental College for Women, Tamil Nadu, India.
المصدر: Journal of pharmacy & bioallied sciences [J Pharm Bioallied Sci] 2022 Jul; Vol. 14 (Suppl 1), pp. S769-S773. Date of Electronic Publication: 2022 Jul 13.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Medknow Publications Country of Publication: India NLM ID: 101537209 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0976-4879 (Print) Linking ISSN: 09757406 NLM ISO Abbreviation: J Pharm Bioallied Sci Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Mumbai, India : Medknow Publications
مستخلص: Introduction: Growing evidence has shown that cyclooxygenase-2 (COX-2), an enzyme capable of catalyzing prostaglandin production, plays a key role in carcinogenesis. Selective COX-2 inhibitors have been shown to reduce the establishment of tumors such as oral squamous cell carcinoma (OSCC) and premalignant conditions such oral submucous fibrosis (OSMF) in experimental models. The aim of this study was to investigate the immunohistochemical expression of COX-2 in OSCC and OSMF with the normal oral mucosa as control.
Material and Methods: Forty-five formalin-fixed paraffin-embedded samples comprising 20 OSCC, 20 OSMF, and 5 normal oral mucosa specimens were withdrawn from the archives of the Department of Oral and Maxillofacial Pathology for immunohistochemical examination for COX-2 expression. Negative and less than 5% COX-2 positivity was considered negative expressions, while greater than or equal to 5% COX-2 positivity was considered positive expression. The data obtained were statistically analyzed.
Results: The difference in percentages of expression in normal mucosa, OSCC, and OSMF was highly significant ( P < 0.01). In comparison to normal mucosa, OSCC and OSMF had an increased level of COX-2 expression. However, there was an insignificant difference between the various histological gradings of OSCC and OSMF.
Conclusion: The results of the present study confirm the role of COX-2 in carcinogenesis and in the progression of premalignant conditions to malignancy.
Competing Interests: There are no conflicts of interest.
(Copyright: © 2022 Journal of Pharmacy and Bioallied Sciences.)
References: Clin Cancer Res. 2004 Mar 1;10(5):1678-84. (PMID: 15014019)
Int J Mol Sci. 2020 Dec 03;21(23):. (PMID: 33287464)
Neoplasia. 2001 Jan-Feb;3(1):53-61. (PMID: 11326316)
Med Oral Patol Oral Cir Bucal. 2009 Jul 01;14(7):E319-24. (PMID: 19300368)
J Oral Pathol Med. 2008 Oct;37(9):535-42. (PMID: 18284542)
Ann Diagn Pathol. 2012 Oct;16(5):354-61. (PMID: 22575501)
Oral Oncol. 2006 Jul;42(6):561-8. (PMID: 16311067)
Natl Med J India. 1998 May-Jun;11(3):113-6. (PMID: 9707699)
J Pharm Bioallied Sci. 2013 Jun;5(Suppl 1):S85-8. (PMID: 23946584)
Int J Mol Sci. 2019 Jun 16;20(12):. (PMID: 31208114)
Oral Oncol. 2003 Dec;39(8):829-35. (PMID: 13679206)
Arch Otolaryngol Head Neck Surg. 2001 Oct;127(10):1253-9. (PMID: 11587608)
J Cancer Res Ther. 2014 Oct-Dec;10(4):1024-9. (PMID: 25579548)
Cancer Res. 1999 Mar 1;59(5):991-4. (PMID: 10070952)
Front Oral Health. 2021 Feb 22;2:642238. (PMID: 35047997)
Oral Oncol. 2005 Mar;41(3):304-12. (PMID: 15743693)
J Oral Maxillofac Pathol. 2019 May-Aug;23(2):301. (PMID: 31516243)
Open Dent J. 2012;6:126-30. (PMID: 22930665)
J Oral Pathol Med. 2003 Mar;32(3):146-53. (PMID: 12581384)
Int J Oral Maxillofac Surg. 2008 Apr;37(4):379-83. (PMID: 18356024)
J Contemp Dent Pract. 2012 Mar 01;13(2):205-9. (PMID: 22665749)
Hua Xi Kou Qiang Yi Xue Za Zhi. 2005 Oct;23(5):431-3. (PMID: 16285555)
Virchows Arch. 2002 Jun;440(6):594-7. (PMID: 12070598)
فهرسة مساهمة: Keywords: Cyclooxygenase 2; dysplasia; oral squamous cell carcinoma; oral submucous fibrosis; premalignant; tobacco
تواريخ الأحداث: Date Created: 20220916 Latest Revision: 20220917
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9469252
DOI: 10.4103/jpbs.jpbs_135_22
PMID: 36110596
قاعدة البيانات: MEDLINE
الوصف
تدمد:0976-4879
DOI:10.4103/jpbs.jpbs_135_22